William Stohl, MD, PhD

Professor of Medicine

Chief, Division of Rheumatology

Is this your profile? Click to edit

Overview

Dr. Stohl’s research focus is on systemic lupus erythematosus (pathogenesis, natural course of disease, treatment, animal models, immunologic disturbances, novel therapeutics); rheumatoid arthritis (pathogenesis, natural course of disease, treatment, animal models, immunologic disturbances, novel therapeutics); Sjogren’s syndrome (biomarkers, novel therapeutics); and B cells (basic biology, role in autoimmune diseases, development of targeted therapies).

Dr. Stohl received his M.D. (1977) and his Ph.D. (1979) from the University Pennsylvania.

Awards

University of Pennsylvania School of Medicine: Upjohn Award, 1979
Arthritis Foundation Southern California Chapter: James R. Klinenberg, M.D. Award, 2003

Research Funding

The vital role of BAFF in the development of SLE
NIH · R01AR050193 · May 16, 2006 – Aug 31, 2012 · Role: Principal Investigator
T CELL CYTOLYTIC ACTIVITY IN SLE
NIH · R01AR041006 · Aug 12, 1993 – Jun 30, 2002 · Role: Principal Investigator
POLYMORPHISM WITHIN T4/LEU3 AND SLE
NIH · R23AR036527 · Jan 1, 1986 – Jun 30, 1989 · Role: Principal Investigator

Media

Publications

The safety of belimumab for the treatment of systemic lupus erythematosus. Expert Opin Drug Saf. 2019 Dec; 18(12):1133-1144.. View in PubMed
Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 07; 71(7):1125-1134.. View in PubMed
IgM Plasma Cells Reside in Healthy Skin and Accumulate with Chronic Inflammation. J Invest Dermatol. 2019 12; 139(12):2477-2487.. View in PubMed
Elevated serum globulin gap as a highly reliable marker of elevated erythrocyte sedimentation rate in patients with systemic rheumatic diseases. Semin Arthritis Rheum. 2019 12; 49(3):485-492.. View in PubMed
Constitutive reduction in the checkpoint inhibitor, CTLA-4, does not accelerate SLE in NZM 2328 mice. Lupus Sci Med. 2019; 6(1):e000313.. View in PubMed
Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study. Lupus Sci Med. 2018; 5(1):e000288.. View in PubMed
Increased Cathepsin S activity associated with decreased protease inhibitory capacity contributes to altered tear proteins in Sjögren’s Syndrome patients. Sci Rep. 2018 07 23; 8(1):11044.. View in PubMed
Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2018 08; 70(8):1256-1264.. View in PubMed
A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus. Lupus. 2018 Aug; 27(9):1489-1498.. View in PubMed
Maternal Serum B-Cell Activating Factor Levels: Candidate Early Biomarker for Hypertensive Disorders of Pregnancy. Hypertension. 2017 11; 70(5):1007-1013.. View in PubMed